Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $130

Benzinga Newsdesk www.benzinga.com Negative 52.9%

Neg 52.9% Neu 0% Pos 0%

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $139 to $130.